EP0954313A4 - Method for treating tumors having high ldl requirements employing mtp inhibitors - Google Patents

Method for treating tumors having high ldl requirements employing mtp inhibitors

Info

Publication number
EP0954313A4
EP0954313A4 EP97932594A EP97932594A EP0954313A4 EP 0954313 A4 EP0954313 A4 EP 0954313A4 EP 97932594 A EP97932594 A EP 97932594A EP 97932594 A EP97932594 A EP 97932594A EP 0954313 A4 EP0954313 A4 EP 0954313A4
Authority
EP
European Patent Office
Prior art keywords
treating tumors
high ldl
mtp inhibitors
employing
requirements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97932594A
Other languages
German (de)
French (fr)
Other versions
EP0954313A1 (en
Inventor
Raymond A Firestone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0954313A1 publication Critical patent/EP0954313A1/en
Publication of EP0954313A4 publication Critical patent/EP0954313A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97932594A 1996-07-24 1997-07-14 Method for treating tumors having high ldl requirements employing mtp inhibitors Withdrawn EP0954313A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2286396P 1996-07-24 1996-07-24
US22863P 1996-07-24
PCT/US1997/012158 WO1998003174A1 (en) 1996-07-24 1997-07-14 Method for treating tumors having high ldl requirements employing mtp inhibitors

Publications (2)

Publication Number Publication Date
EP0954313A1 EP0954313A1 (en) 1999-11-10
EP0954313A4 true EP0954313A4 (en) 2003-07-02

Family

ID=21811838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97932594A Withdrawn EP0954313A4 (en) 1996-07-24 1997-07-14 Method for treating tumors having high ldl requirements employing mtp inhibitors

Country Status (4)

Country Link
EP (1) EP0954313A4 (en)
JP (1) JP2002513379A (en)
CA (1) CA2261162A1 (en)
WO (1) WO1998003174A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
SI1725234T1 (en) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
WO2005094864A2 (en) * 2004-03-30 2005-10-13 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis
US20230346762A1 (en) * 2020-02-21 2023-11-02 Korea Advanced Institute Of Science And Technology Pharmaceutical composition for preventing or treating cancer, containing mtor-signaling inhibitor as active ingredient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584446A2 (en) * 1992-03-06 1994-03-02 E.R. SQUIBB & SONS, INC. Microsomal triglyceride transfer protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584446A2 (en) * 1992-03-06 1994-03-02 E.R. SQUIBB & SONS, INC. Microsomal triglyceride transfer protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MALTESE, W. A.; DEFENDINI, R.; GREEN, R. A.; SHERIDAN, K. M.; DONLEY, D. K.: "Suppression of Murine Neuroblastoma Growth In Vivo by Mevinolin, a Competitive Inhibitor of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase", JOURNAL OF CLINICAL INVESTIGATION, vol. 76, - 1 November 1985 (1985-11-01), pages 1748 - 1754, XP009010279 *
MIKULSKI S M ET AL: "SYNERGISM BETWEEN A NOVEL AMPHIBIAN OOCYTE RIBONUCLEASE AND LOVASTATIN IN INDUCING CYTOSTATIC AND CYTOTOXIC EFFECTS IN HUMAN LUNG AND PANCREATIC CARCINOMA CELL LINES", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 66, no. 2, August 1992 (1992-08-01), pages 304 - 310, XP000857575, ISSN: 0007-0920 *
See also references of WO9803174A1 *
THIBAULT, A; SAMID, D; TOMPKINS, A C; FIGG, W J; COOPER, M R; HOHL R J; TREPEL, J; LIANG, B; PATRONAS, N; VENZON, D J; REED, E: "Phase I Study of Lovastatin, an Inhibitor of the Mevalonate Pathway, in Patients with Cancer", CLINICAL CANCER RESEARCH, vol. 2, pages 483 - 491, XP001147434 *

Also Published As

Publication number Publication date
EP0954313A1 (en) 1999-11-10
JP2002513379A (en) 2002-05-08
CA2261162A1 (en) 1998-01-29
AU3600897A (en) 1998-02-10
WO1998003174A1 (en) 1998-01-29
AU712303B2 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
AU1527897A (en) Method for treating the prostate
PL330782A1 (en) Method of treating carcinoma using the inhibitors of naaladase
AU3813397A (en) Apparatus for treating chondromalicia
AU3829895A (en) Methods for treating resistant tumors
AU2543097A (en) Method for treating pain
IL126759A0 (en) Method for treating inflammation
HK1039449A1 (en) Methods for treating multiple sclerosis
AU2340897A (en) Method for treating pain
AU4672597A (en) Method for treating urinary reflux
AU2584597A (en) Method for treating migraine pain
EG23945A (en) Method for treating COPD
EP0954313A4 (en) Method for treating tumors having high ldl requirements employing mtp inhibitors
AU6688798A (en) Method for treating lumber
AU9615198A (en) Magnetic apparatus for treating fluid fuels
IL126162A0 (en) Method for treating bipolar disorder
HUP9903779A3 (en) Method for treating amyotrophic lateral sclerosis
AU7602896A (en) Methods for treating resistant tumors
AU5369498A (en) Compounds and methods for treating cancer
AU3896597A (en) Method for treating substance abuse
AU4228997A (en) Method for treating homozygous familial hypercholesterolemia
GB9517701D0 (en) Method for treating hyperlipidemia
EP1043994A4 (en) Method for treating multiple sclerosis
AU2198997A (en) Method for treating insomnia
AU7104898A (en) Synergistic method for treating cancer
SI0667175T1 (en) Method for treating edges of skis etc.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030519

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 31/00 B

Ipc: 7A 61P 3/06 B

Ipc: 7A 61K 31/445 A

17Q First examination report despatched

Effective date: 20030922

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040203